Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oragenics Inc (NY: OGEN )

0.2706 -0.0174 (-6.04%)
Official Closing Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oragenics Inc

< Previous 1 2 Next >
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Oragenics to Present at Centurion One Capital 2nd Annual Bahamas Summit
Via Investor Brand Network
BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Concussion Treatment with Promising Study for Nasal Spray Drug ONP-002
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Closes on $4.45M Public Offering
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
Via Investor Brand Network
Exposures Product Safety
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Closing of Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Pricing of Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Proposed Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces Leadership Transition
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Termination of At-The-Market Offering Program
From Oragenics, Inc.
Via Business Wire
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
From Oragenics, Inc.
Via Business Wire
Oragenics Issues Update to Shareholders
From Oragenics
Via Business Wire
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
From Oragenics, Inc.
Via Business Wire
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
From Oragenics, Inc.
Via Business Wire
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces Private Placement
From Oragenics, Inc.
Via Business Wire
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
From Oragenics, Inc.
Via Business Wire
Oragenics to Participate in the World Vaccine Congress Washington
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
From Oragenics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.